Stamulumab Reference: HY-P99588 Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research.
Elotuzumab Reference: HY-P9965 Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.
Sampeginterferon beta-1a Reference: HY-P99897 Sampeginterferon beta-1a (BCD-054) is a pegylated IFNβ-1a. Sampeginterferon beta-1a can be used for research against remitting multiple sclerosis.
Pulocimab Reference: HY-P99808 Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers.
Anti-Mouse CD11a Antibody Reference: HY-P99120 Anti-Mouse CD11a Antibody is an anti-mouse CD11a IgG2b antibody inhibitor derived from the host Rat.
Etanercept Reference: HY-108847 Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
Talacotuzumab Reference: HY-P99395 Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models.
Gremubamab Reference: HY-P99649 Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections.
Anti-Mouse IFN gamma Antibody Reference: HY-P99136 Anti-Mouse IFN gamma Antibody is an anti-mouse IFN gamma IgG antibody inhibitor derived from host Armenian Hamster.
Timolumab Reference: HY-P99323 Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases.
Revdofilimab Reference: HY-P99945 Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells.